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ABSTRACT

MARY VIRGINIA PORTERA: Redox-sensitive Block Copolymer Nanoparticle
Preparation and Characterization (under the direction of Dr. Seongbong Jo)
The purpose of the research conducted in this project was to add to a wealth of
knowledge concern chemotherapy. Although chemotherapy has been used since Paul
Ehrlich’s discover of Salvarsan’s ability to kill Treponema pallidum (the bacteria that
cause syphilis), today the term chemotherapy is mostly used in conjunction with cancer
treatment. There have been many successful chemotherapy drugs produced throughout
the years, but a constant problem with chemotherapy is the fact that it also affects
noncancerous cells.
The topic of this research investigated targeted drug delivery systems that
incorporate paclitaxel, a hydrophobic chemotherapy drug. This research mainly focused
on producing findings that work to stabilize drug delivery systems for paclitaxel while
also allowing for its predictable release in a reduced environment that mimics a typical
cancerous cell.
The mixed micelle approach used Pluronic® poloxamers and redox-sensitive
copolymers to create a drug delivery system that could interact with not only
hydrophobic paclitaxel but also a hydrophilic aqueous environment that mimics the
environment of a cancerous cell. The result of these redox-sensitive block copolymers is
to produce an amphiphilic drug delivery system that will release paclitaxel upon
interaction with a cancerous cell environment and not a healthy cell environment.

TABLE OF CONTENTS
LIST OF TABLES..............................................................................................................ix
LIST OF ABBREVIATIONS.............................................................................................xi
INTRODUCTION...............................................................................................................1
METHODOLOGY............................................................................................................12
RESULTS AND DISCUSSION........................................................................................18
CONCLUSION .................................................................................................................33
LIST OF REFERENCES...................................................................................................35

viii

LIST OF FIGURES AND TABLES
Figure 1

Paclitaxel......................................................................................................2

Figure 2

Unpaired polyQPA.......................................................................................4

Figure 3

Hydrophobic polyQPA paired with hydrophilic polyethylene glycol
chain.............................................................................................................5

Figure 4

Proposed reaction mechanism of DT-diaphorase interaction with
polyQPA-mPEG750......................................................................................7

Figure 5

Representation of polyQPA-mPEG750 micelle and drug release.................8

Figure 6

Generic structure of a Pluronic® molecule..................................................9

Figure 7

Representation of polyQPA-Pluronic® redox-sensitive block copolymer
micelle and drug release.............................................................................11

Figure 8

Size distribution and Z-average diameter of the Pluronic® F68 redoxsensitive block copolymers in Sample 1 at Time Zero..............................19

Figure 9

Size distribution and Z-average diameter of the Pluronic® P85 redoxsensitive block copolymers in Sample 1 at Time Zero..............................20

Figure 10

Size distribution and Z-average diameter of the Pluronic® F127 redoxsensitive block copolymers in Sample 1 at Time Zero..............................21

Figure 11

Changes in Z-average diameter size over 37 days in the three Pluronic®
samples.......................................................................................................28

Figure 12

Change in Z-average size after addition of sodium dithionite over 130
minutes.......................................................................................................31

Table 1

Time zero particle Z-average size characterization...................................18

Table 2

Size on October 26, 2015 (Day 1).............................................................18

Table 3

Size measurement on October 27, 2015 (Day 2).......................................22

Table 4

Size measurement on October 28, 2015 (Day 3).......................................23

Table 5

Size measurement on October 29, 2015 (Day 4).......................................23

ix

Table 6

Size measurement on October 30, 2015 (Day 5).......................................24

Table 7

Size measurement on November 2, 2015 (Day 8).....................................24

Table 8

Size measurement on November 5, 2015 (Day 11)...................................25

Table 9

Size measurement on November 9, 2015 (Day 15)...................................25

Table 10

Size measurement on November 12, 2015 (Day 18).................................26

Table 11

Size measurement on November 19, 2015 (Day 25).................................26

Table 12

Size measurement on December 1, 2015 (Day 37)....................................27

Table 13

Change in Z-average size after addition of sodium dithionite over 130
minutes.......................................................................................................30

LIST OF ABBREVIATIONS
polyQPA

trimethyl-locked quinone propionic acid

mPEG750

hydrophilic polyethylene glycol

NADPH

nicotinamide adenine dinucleotide phosphate

PEO

polyethylene oxide

PPO

polypropylene oxide

NasS2O4

sodium Dithionite

PVA

polyvinyl alcohol

PBS

phosphate buffered saline

CH2Cl2

dichloromethane

PDI

polydispersity index

DLS

dynamic light scattering

INTRODUCTION
There have not been many fields of research that have been more widespread than
the area of cancer research. Although an overarching term that describes a multitude of
diseases, at its core, cancer is an excess proliferation of abnormal cells that continue to
divide uncontrollably and ultimately invade other tissues. The topic of this research aims
to generate and characterize potential drug delivery systems for cancer drug use.
Although the subject of this research focuses on nanoparticle drug delivery
systems, it is important first to understand the drug and some of its properties in order to
better understand the overall mechanism of the drug delivery system. The drug with
which the drug delivery system is targeted to incorporate is paclitaxel, a class of
hydrophobic chemotherapy drugs. The chemical structure of paclitaxel is shown in Figure
1. Paclitaxel’s function is to prevent microtubule formation in cells, thus precluding the
cells’ ability to divide during the process of mitosis (“Taxol”). Paclitaxel has proven to be
a very potent and successful chemotherapy agent; however, it is also essentially
nonselective and will not only attack cancer cells, but also normal, functionally important
cells in the body. Therefore, the effects of this nonselective attack can lead to adverse
side-effects and possible ineffective treatment (Bae and Nael et al. 1). Drug delivery
systems solve the problem of nonselective delivery by using a targeted delivery
mechanism. There are several types of targeted delivery, in which the conditions in the
target cell (in this case, the cancer cell) induce the delivery system to release the drug and
perform its function in the target cell. Drug delivery systems produced to incorporate and
deliver paclitaxel in a cancerous cell environment are the topic of this research.
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Figure 1. Paclitaxel
Source: “Taxol.” Chemocare. Cleveland Clinic, 2014. Web. 27 October 2015.
Preliminary research investigated the effects of using redox-sensitive polymeric
nanoparticles as targeted drug delivery systems. This approach was formulated on the
basis of a differing redox gradient state between normal cells and cancerous cells. This
redox gradient is thought to be caused by a reductase enzyme called DT-diaphorase that
is overly expressed in many types of tumor cells (Bae and Maurya et al. 2). Specifically,
cancerous lung and pancreatic cells have been shown to overexpress this enzyme. DTdiaphorase is a two-electron reductase, and in some cancerous cells like that of lungs and
of the pancreas, there is as much as a 20-fold increase in its levels than in levels in
normal tissue (Bae and Maurya et al. 2). As a result, these cells, and possibly other types
of cancerous cells, have a reduced environment. The way a targeted delivery system
works in this case is that the redox gradient between the extracellular environment and
the intracellular environment is the cue for drug release. When the delivery system
encounters the more reduced cellular environment, the system releases the drug into the
cell, allowing it to perform its function. This property was thus targeted in preliminary
research as a way to design a redox-sensitive paclitaxel delivery system.
Not only do successful drug delivery systems need to be targeted to specific cells
in order to be functional, but they also need to have the qualities of stability and solvency
2

in order to be viable. Stability refers to the ability of drug delivery systems to maintain
their structure and thus size over a period of time. If a drug delivery system is functional
but degenerates over a short period of time, it will not be a viable option for actual drug
delivery. Solvency refers to the fact that the nanoparticles of the system must not selfaggregate but must disperse freely in order to react and interact with the cellular
environment and function properly. In this study, one type of polymeric delivery system
was produced by incorporation of different types of poloxamers into a redox-responsive
polymer in order to make stable paclitaxel polymeric drug delivery system based on a
mixed micelle approach.
The specific polymer used in this research was poly-trimethyl-locked quinone
propionic acid (polyQPA) shown in Figure 2. This polymer is hydrophobic, and
therefore, it tends to aggregate in solution rather than disperse and dissolve freely. In
preliminary research by Bae, et. al, this polymer was reacted with a hydrophilic
polyethylene glycol (mPEG750) chain to produce the nanoparticle shown in Figure 3. The
preliminary research provides a basic understanding of the mechanisms and
characteristics of the system. In solution, the hydrophobic polyQPA portion is
sequestered from water, but the hydrophilic mPEG750 chains stretch toward water to
make a micelle. In the drug delivery system with drug incorporated, hydrophobic
paclitaxel interacts with polyQPA in the core of the micelle. The hydrophilic mPEG750
chains that protrude from the structure act to stabilize the micelle and prevent complete
aggregation of the hydrophobic portions of the micelle. The structure of the micelle can
be seen in Figure 5. This resulting nanoparticle structure with a mixture of hydrophobic
and hydrophilic properties was designed to better distribute in a cancerous cell and allow
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the mechanism of the drug delivery system to occur. The mechanism of how this reaction
occurs and what happens as a result with paclitaxel will be explained next. It is also
important to note that the main research associated with this redox-sensitive block
copolymer project used poloxamers as copolymers paired with polyQPA rather than
mPEG750 chains. The mention of mPEG750 chains now is just to give preliminary
understanding of the research history, and the mechanisms associated with the poloxamer
copolymers will be described later.

Figure 2. Unpaired polyQPA
Source: Bae, Jungeun, Abhijeet Maurya, Zia Shariat-Madar, S. Narasimha Murthy, and
Seongbong Jo. “Novel Redox-Responsive Amphiphilic Copolymer Micelles for Drug
Delivery: Synthesis and Characterization.” American Association of Pharmaceutical
Scientists (2015): 1-12. Print.
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Figure 3. Hydrophobic polyQPA paired with hydrophilic polyethylene glycol chain
Source: Bae, Jungeun, Abhijeet Maurya, Zia Shariat-Madar, S. Narasimha Murthy, and
Seongbong Jo. “Novel Redox-Responsive Amphiphilic Copolymer Micelles for Drug
Delivery: Synthesis and Characterization.” American Association of Pharmaceutical
Scientists (2015): 1-12. Print.
The proposed mechanism of the reaction inside a cancerous cell not only depends
on the reduced environment property of the cells owing to DT-diaphorase but also to the
micelle properties of the polyQPA-mPEG750. Upon release in solution, the resulting
nanoparticle tends to aggregate, but in a predictable and meaningful way with the
hydrophobic portion at the core interacting with incorporated paclitaxel, and the
hydrophilic chains protruding in a formation called a micelle. What would ideally occur
with the reaction mechanism in a cancerous cell is that the polyQPA-mPEG750 molecule
would enter the cell, and one of the carboxyl groups of the cyclic portion of the polyQPA
would be protonated due to the action of reductive enzyme. This would result in a
cyclization reaction producing a hydroquinone. One of the hydroxyl groups in the
hydroquinone would then act as a nucleophile and attack the carboxyl group attached to
the amide group in a nucleophilic acyl substitution reaction, where the amide group
would be cleaved. Therefore, resultant free amine group in the mPEG750 copolymer
becomes hydrophilic. As a result, the balance between hydrophobic polyQPA and
5

mPEG750 would be broken essentially to dissemble the micellar structure. Thus,
paclitaxel that was previously stored inside the micelle would be released. Therefore, at
this point, freed paclitaxel is able to function in the cancerous cell, while not being
present in healthy and non-cancerous cells, because DT-diaphorase is not present in
enough volume in healthy cells to cause the reaction (Mattern). Figure 4 shows the
reaction mechanism, and Figure 5 illustrates the macroscopic process of what would
occur. In Figure 4, NADPH (shown as H2) would act mechanistically as electron donor
for DT-diaphorase-mediated bioreduction.
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Figure 4. Proposed reaction mechanism of DT-diaphorase interaction with polyQPAmPEG750
Source: Mattern, Daniell. Personal Interview. 20 October 2015.
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Figure 5. Representation of polyQPA-mPEG750 micelle and drug release
Source: Bae, Jungeun, Abhijeet Maurya, Zia Shariat-Madar, S. Narasimha Murthy, and
Seongbong Jo. “Novel Redox-Responsive Amphiphilic Copolymer Micelles for Drug
Delivery: Synthesis and Characterization.” American Association of Pharmaceutical
Scientists (2015): 1-12. Print.
Although the previous set of nanoparticles shows promise, the type that was
investigated as the main subject of this research was mixed micelles of polyQPA and
Pluronic®. Pluronic® is the registered name for the poloxamers used in this experiment.
There are several reasons incorporating Pluronic® was proposed to be an effective
alternative to the mPEG750 chain. One of the most important parts of a drug delivery
system is its stability, or its ability to remain the same size and not degenerate over a
period of time. Pluronic® poloxamers contain hydrophilic and hydrophobic portions that
work to stabilize polyQPA. The hydrophilic portion is the polyethylene oxide (PEO)
chains that are labeled A and C in Figure 6, and the hydrophobic portion is a
polypropylene oxide (PPO) core that is labeled B.
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Figure 6. Generic structure of a Pluronic® molecule

Pluronic® copolymers have several characteristics that make them excellent as
drug delivery systems. First, the amphiphilic nature of Pluronic® copolymers allow them
the ability to interact with not only the hydrophobic polyQPA without covalently binding
to it but also with hydrophobic paclitaxel. The PPO portion labeled B in Figure 6 is the
portion that interacts hydrophobically with polyQPA and paclitaxel. Therefore, it
stabilizes the overall structure of the molecule without requiring covalent bonds that
would need to be broken during the course of drug delivery. It allows polyQPA to
perform its same function and mechanism of drug delivery and provides stabilization so
the drug delivery system can last over a longer period of time. Second, solvency is
another very important characteristic of drug delivery systems. The hydrophilic portion of
the Pluronic® copolymers that is labeled A and C in Figure 6 acts as would the mPEG750
chain by forming around the hydrophobic portion and allowing the individual
nanoparticles to disperse freely and not self-aggregate (Batrakova and Kabanov 2). If the
systems were too hydrophobic, they would aggregate together and become too large and
cumbersome to enter into cells and perform their delivery function. This amphiphilic
nature of Pluronic® copolymers should create more stable nanoparticles that are able to
exist for longer periods of time than formerly generated nanoparticles, while also
maintaining their dispersal ability. Third, the hydrophobic PPO portion also allows the
resulting nanoparticle to incorporate into the cellular membrane of tumor cells. As a
9

result, the fluidity of the membrane decreases, which is of vital importance to the cell’s
survival (Batrakova and Kabanov 4). According to Batrakova and Kabanov, a decrease in
membrane viscosity also decreases the drug efflux activity of tumor cells, which means
that the mechanism in tumor cells that usually allows them to expel drugs would be
inhibited by Pluronic®’s incorporation into the cell membrane. Therefore, for these
reasons, Pluronic® was used as the block copolymer associated with polyQPA. Next, the
characterization of Pluronic® copolymers used will be detailed.
Because Pluronic® is a class of block copolymers, there are different types that are
more effective to use in certain situations. The three used in this research were Pluronic®
P85, F68, and F127. The reasons for choosing Pluronic® P85, F68, and F127 were
reasons of availability and also existing literature about the best Pluronic® copolymers
already tested for drug delivery (Almeida et al.; Batrakova and Kabanov; Csaba et al.).
All three have been widely researched, and therefore, the target of this research is to
incorporate them with polyQPA, a redox-sensitive polymeric nanoparticle in order to
generate redox-sensitive block copolymeric nanoparticles. The letter in front (P or F)
indicates the state of the substance at room temperature. For example, Pluronic® P85, is a
paste at room temperature, while Pluronic® F68 is a flake (solid) at room temperature.
The first number (or two number) multiplied by 100 gives the molecular weight of the
polypropylene oxide portion, while the last number multiplied by 10 gives the percent
content of polyethylene oxide (Batrakova and Kabanov 2). Pluronic® P85 is the least
hydrophilic of the three used in this research at 50% hydrophilic, while Pluronic® F68 is
the most hydrophilic at 80%. Therefore, it was hypothesized that in this research,
Pluronic® P85 and polyQPA will show the most aggregation and Pluronic® F68, the least.
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Figure 7 shows the micelles and proposed drug release with the redox-sensitive block
copolymers. As stated previously, the same mechanism described in Figure 3 is expected
to function with the polyQPA and Pluronic® paired redox-sensitive block copolymers.

Figure 7. Representation of polyQPA-Pluronic® redox-sensitive block copolymer micelle
and drug release
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METHODOLOGY
In this experiment, Pluronic® F127, F68, and P85 were mixed with polyQPA to
prepare micelles. Then, their stability and solvency were tested to see which would be
stable and viable systems for further research. Finally, their ability to perform the
mechanism described in Figure 4 upon addition of sodium dithionite to mimic the
reduced environment of a cancerous cell was tested in order to see if they are functioning
delivery systems.

Preparation of nanoparticles by single emulsion method
The polyQPA without the mPEG750 chain had previously been synthesized, and
therefore, it was used in conjunction with the three Pluronic® copolymers to generate
three different types of redox-sensitive block copolymers. First, the polyQPA-Pluronic®
F68 nanoparticles were made, and 21.47 mg of the polyQPA was placed in a test tube
with 25.73 mg of Pluronic® P85. Next, polyQPA- Pluronic® F127 was made by mixing
21.89 mg of polyQPA with 24.68 mg of Pluronic® F127. Finally, polyQPA- Pluronic®
P68 was made by mixing 20.44 mg of polyQPA with 24.32 mg of Pluronic® F68. Each
sample was in its own test tube. Next, 2 mL of dichloromethane (CH2Cl2) was added to
each test tube to dissolve the particles. Next, for each separate sample, 5.4 mL of 5%
polyvinyl alcohol (PVA) and 12.6 mL of phosphate-buffered saline (PBS) buffer were
added to a beaker using the dilution method. These additions created three separate 1.5%
PVA with PBS buffered solutions in separate beakers to which each nanoparticle and
CH2Cl2 mixture was added. Next, each sample was stirred at 1000 rpm at room
temperature for 10 minutes, and then vacuum stirred in a Buchi® distilled vacuum pump
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for 1-2 minutes to remove the organic solvent, CH2Cl2, from the mixture. Then, each
sample was emulsified by ultrasonic processing for 5 minutes, while being placed in an
ice-bath at the time. The type of emulsifier used was a Sonics and Materials® Vibra-cell
ultrasonic processor with a pulse of 15 seconds and rest period of 15 seconds at an
amplitude of 60%. Then, the three separate mixtures were stirred overnight at room
temperature and 400 rpm.
After being stirred overnight, each solution was filtered to remove large size
particles and the resulting solution with smaller particles was further used. Next, each of
the samples was split into 24 separate portions that were put into separate test tubes
(creating 72 test tubes with approximately 1mL of sample in each). The remainder of the
space in the test tube was filled with PBS. Then, these particles were sonicated in the
Branson® 2800 sonicator for 20 minutes in a 25°C deionized water bath. Next, these
particles were placed in a Fisher Scientific® accuSpin Micro 17 centrifuge for 5 min at
6000 rpm.
Then, the washing process began to remove impurities from the samples. First,
the top layer of liquid was removed (with the particles visible at the bottom) from each of
the 24 test tubes for each sample and distilled water was added to fill each back to the
top. Then, the particles were sonicated using the previously used settings. Next, the
particles were placed in the centrifuge at the same settings, and afterward, the top layer of
liquid was removed and then replaced with new distilled water. Then, the samples were
sonicated again, and centrifuged once more. After this final centrifugation, the top layer
of liquid was not removed. The sample was sonicated one last time. Then for each of the
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three cumulative samples, the solution in each test tube was filtered into a beaker,
creating three beakers with the solutions from the 24 test tubes for each.
Then each of the three beakers was transferred to containers used for freeze
drying (also known as lyophilizing). Each of the three samples was lyophilized in a
Labconco® Freezone freeze dryer with an Edwards® XDS5 pump for 72 hours to remove
all liquid and only have nanoparticles remaining. Then, the nanoparticles were collected
and placed in a So-Low® Ultra-Low -80°C freezer until nanoparticle characterization
work was done.
One of the benefits of this mixed micelle approach to produce polyQPAPluronic® particles as opposed to synthesizing amphiphilic block copolymers like
polyQPA-mPEG750 is that mixed micelle polymers are simpler to synthesize because they
can avoid multi-step reactions that are required to make amphiphilic block copolymers.
This reduction in complexity leads to less time and more reproducibility.

Nanoparticle characterization - Size and Stability
In order to determine the size of the redox-sensitive block copolymers, the
Malvern® Zetasizer Nano ZS was used. The dried nanoparticles each had to be placed
into test tubes. First, 13.12 mg of polyQPA-Pluronic® P85 was placed in a test tube with
2 mL of distilled and deionized HPLC grade water that had previously been filtered in
order to obtain accurate and precise results. Then, 13.66 mg of polyQPA-Pluronic® F68
was put in a test tube with water, and then 13.01 mg of polyQPA-Pluronic® F127 was
placed in a test tube with water. These three test tube samples were placed in the
Branson® 2800 sonicator for 20 minutes at 25°C. Then, portions of each of three samples
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were placed in cuvettes and measured for size in the Zetasizer Nano ZS. This same
procedure was conducted every day for five days in a row, and then twice a week for two
weeks. Then, it was conducted one week later, and then two weeks later to determine its
size stability over time to find the most stable of the three nanoparticles.
The three primary measurements taken using the Zetasizer Nano ZS were the
average Z-average size of the diameter of the nanoparticles, the polydispersity index
(PDI), and the peak intensity distribution. The Zetasizer Nano ZS measures particle size,
molecular weight, and zeta potential of nanoparticles, but in this particular experiment,
only particle size was measured. The Zetasizer Nano ZS measures particle size by
measuring how quickly the particles in solution are moving. The particles move around
by Brownian motion, or the random movement of particles due to the bombardment of
some force. The Zetasizer Nano ZS uses dynamic light scattering (DLS) to bombard the
particles with a laser light that scatters the particles according to their size, meaning that
larger particles will move slower than smaller particles (Zetasizer Nano Series User
Manuel 95). Then, the machine manipulates sophisticated algorithms to determine the
size of the particles based on their movements. The Z-average size measured is the actual
size of the average particles in the sample, and the PDI is the measurement of size
distribution, a kind of standard deviation measurement method. If the PDI was 1.0, it
would mean that the size distribution of the sample was maximal, with very small
particles and very large aggregated particles present, along with intermediately sized
particles as well. A smaller measurement of PDI would mean that most of the particles
are close to the Z-average size. The peak intensity is the range of intensity values within
the peak. Therefore, if the peak’s average is 600 nm for its Z-average size and extends
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from 400 nm to 800 nm, its peak intensity distribution is 400 nm or the difference
between the smallest and largest values in the peak.

Chemical reduction using sodium dithionite (Na2S2O4)
In order to discover the particles’ ability to potentially release paclitaxel, the
polyQPA-Pluronic® block copolymers were reduced by sodium dithionite (Na2S2O4).
Na2S2O4 acts on the nanoparticles through the proposed mechanism in Figure 4 much like
a reduced state in a cancerous cell would act on the nanoparticles.
First, 3.05 mg of polyQPA-Pluronic® F68 was suspended in 1 mL of distilled and
deionized HPLC grade water that had previously been filtered. Next, 3.20 mg of
polyQPA-Pluronic® P85 and 3.01 mg of polyQPA-Pluronic® F127 were added to water
in the same fashion. Then, these samples were flushed with nitrogen gas to remove
atmospheric oxygen. If not removed, atmospheric oxygen would react with Na2S2O4 in a
way that would prevent Na2S2O4 from carrying out the mechanism needed for paclitaxel
release. Next, three samples of 0.122 g of Na2S2O4 was measured for each polyQPAPluronic® sample. This amount of 0.122 g of Na2S2O4 is a 200-fold molar excess of
Na2S2O4 used to ensure that all of the nanoparticles react with the reducing agent. These
Na2S2O4 samples were then flushed with nitrogen gas as well. Next, the samples were
taken to the Zetasizer Nano ZS to measure size as a function of release capability. At
time zero, first polyQPA-Pluronic® F68 was added to Na2S2O4 and was immediately
measured for size. Then, polyQPA-Pluronic® P85 and polyQPA-Pluronic® F127 were
measured for size the same way at time zero. The three samples were continuously
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measured for 130 minutes to determine the change in size of the particles and ultimately
their release ability.

17

RESULTS AND DISCUSSION
Nanoparticle characterization - Size and Stability
Pluronic® F68

Pluronic® P85

Pluronic® F127

Sample 1

405.5 nm

1455 nm

508.1 nm

Sample 2

485.2 nm

926.2 nm

510.5 nm

Sample 3

418.6 nm

1003.1 nm

544.6 nm

Table 1. Time zero particle Z-average size characterization

Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

436.4 ± 42.7 nm

1128.1 ± 285.7 nm

521.1± 20.4 nm

PDI (of Sample 1)

0.071

1.000

0.221

202.5 nm

485.6 nm

Peak Intensity
458.0 nm
Distribution (of
Sample 1)
Table 2. Size on October 26, 2015 (Day 1)
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Figure 8. Size distribution and Z-average diameter of the Pluronic® F68 redox-sensitive
block copolymers in Sample 1 at Time Zero
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Figure 9. Size distribution and Z-average diameter of the Pluronic® P85 redox-sensitive
block copolymers in Sample 1 at Time Zero
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Figure 10. Size distribution and Z-average diameter of the Pluronic® F127 redoxsensitive block copolymers in Sample 1 at Time Zero

The first measurement of size of the samples shows that the Pluronic® P85 sample
has the largest nanoparticles, and these are too large to even be potential drug delivery
systems for further research. The typical eukaryotic cell has a diameter between 10-500
µm or 10,000-500,000 nm. Therefore, a drug delivery system of 1128.1 ± 285.7 nm in
diameter will be too large to incorporate into the cell membrane productively. This
finding about Pluronic® P85 holds well with the earlier hypothesis that it was the most
hydrophobic sample, and therefore would aggregate the most. Indeed, this sample
produced the most aggregated nanoparticles, and thus the largest size readings of the
nanoparticles. Furthermore, the Pluronic® P85 sample also had a PDI of 1.000, meaning
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that 1128.1 ± 285.7 nm is not an accurate representation of the size of all of them, just an
average. Some of the particles were probably smaller than this average, while others
larger. The Pluronic® F58 and F127 samples both contain nanoparticles too large for drug
delivery; however, they are considerably smaller than P85 and there are the most
important in the remainder of the measurements and further research to create viable
delivery systems. Their PDI values are significantly lower, with Pluronic® F68 having the
smallest PDI, and therefore, the best representative Z-average size. The range of sizes in
the peaks were similar for Pluronic® F68 and F127, while Pluronic® P85 had a much
smaller width, probably owing to the fact that most particles in the sample were varying
sizes not within that peak range.

Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

378 nm

895.2 nm

595.8 nm

PDI

0.192

0.621

0.456

Peak Intensity
Distribution

427.9 nm

1) 642.3 nm
2) 89.38 nm
*two peaks
detected
Table 3. Size measurement on October 27, 2015 (Day 2)

364.9 nm

The Day 2 measurements saw an overall decrease in Z-average size, but not be
too wide of a margin. Pluronic® F68 and F127 still had the most reliable PDI scores and
acceptable Z-average sizes, with similar peak ranges. However, Pluronic® P85 showed
two peaks, meaning that most particles were found to be of the sizes that those peaks
represented. Nevertheless, the PDI is still larger than the ideal value, and therefore, there
were many particles in the sample with many different sizes.
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Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

407.6 nm

1125 nm

581.6 nm

PDI

0.348

0.768

0.365

Peak Intensity
378.5 nm
366.9 nm
Distribution
Table 4. Size measurement on October 28, 2015 (Day 3)

419.5 nm

The Day 3 measurement shows little change for Pluronic® F68 and F127,
confirming that they are the most reliable and stable samples. Pluronic® P85 again has a
very large PDI value, demonstrating that many of the particles are of different sizes, and
therefore, not a good sample for subsequent drug delivery.

Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

435.6 nm

1071 nm

670.2 nm

PDI

0.348

0.811

0.675

Peak Intensity
376.9 nm
312.3 nm
Distribution
Table 5. Size measurement on October 29, 2015 (Day 4)

297.0 nm

The day 4 measurements show a suitable Z-average size for Pluronic® F68, but a
very much enlarged Z-average size and PDI for Pluronic® F127. Pluronic® P85 still
continues to show an unsuitable size and PDI value. Therefore, at this point, Pluronic®
F68 seems to be the most stable and suitable sample.
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Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

431.1 nm

1267 nm

597.4 nm

PDI

0.287

0.960

0.591

Peak Intensity
386.5 nm
279.1 nm
Distribution
Table 6. Size measurement on October 30, 2015 (Day 5)

300.7 nm

The day 5 measurements are very similar to day 4, with Pluronic® F127 coming
back into a suitable range for Z-average size and PDI. Pluronic® F68 still looks most
promising.

Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

671.7 nm

2277 nm

601.1 nm

PDI

0.519

1.000

0.552

Peak Intensity
Distribution

1)272.4 nm
122.4 nm
2) 428.9 nm
*two peaks
detected
Table 7. Size measurement on November 2, 2015 (Day 8)

297.7 nm

The day 8 measurements show a destabilization of Pluronic® F68, with Pluronic®
F127 now being the most stable of the three. Pluronic® F68 also had two peaks detected,
revealing that the particle sizes have separated into two peaks, or two predominant groups
of sizes. Pluronic® P85 has an even larger Z-average size value, and the PDI is now at
1.000, revealing that the particles are all of different sizes in the sample.
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Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

493.6 nm

2671 nm

542.1 nm

PDI

0.309

1.000

0.442

Peak Intensity
309 nm
78.82 nm
Distribution
Table 8. Size measurement on November 5, 2015 (Day 11)

376.3 nm

The day 11 measurements have Pluronic® F68 once again with a suitable Zaverage size and PDI value, along with suitable values for Pluronic® F127.

Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

607.1 nm

2428 nm

511.1 nm

PDI

0.429

1.000

0.278

Peak Intensity
440.6 nm
116.2 nm
Distribution
Table 9. Size measurement on November 9, 2015 (Day 15)

455.9 nm

On day 15, Pluronic® F68 shows a significant increase in size, with Pluronic®
F127 remaining steady and stable, with a low PDI value. Their peak intensity
distributions have both increased, showing that most of the particles that are within the
peak range of measurements have started to spread out. Therefore, it is likely that after
this point, they will continue to increase in size and decrease in stability.
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Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

769 nm

2128 nm

531.9 nm

PDI

0.553

1.000

0.427

Peak Intensity
386.6 nm
187.2 nm
Distribution
Table 10. Size measurement on November 12, 2015 (Day 18)

361.8 nm

The day 18 measurements reveal that Pluronic® F68’s Z-average size is much too
large now, while Pluronic® F127 is the most stable to this point. Pluronic® P85
continues to be much to large, with a maximal PDI value.

Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

921.3 nm

2587 nm

598. 2 nm

PDI

0.560

1.000

0.449

Peak Intensity
604.9 nm
105.7 nm
Distribution
Table 11. Size measurement on November 19, 2015 (Day 25)

449.2 nm

The day 25 measurements reveal that Pluronic® F68 continues to increase and will
likely not go back to its smaller value. Therefore, it can be assumed that its threshold for
stability ended after the day 11 or or even possibly after the day 8 measurements.
Pluronic® F127 increased as well, with an increase in PDI as well as an increase in its
peak intensity distribution. Therefore, it is likely that at this point, Pluronic® F127 has hit
its threshold for stability.
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Pluronic® F68

Pluronic® P85

Pluronic® F127

Z-average size

1053 nm

2348 nm

753.3 nm

PDI

0.712

1.000

0.585

Peak Intensity
415.7 nm
152.2 nm
Distribution
Table 12. Size measurement on December 1, 2015 (Day 37)

575.9 nm

The final measurements taken on day 37 show a destabilization in all three
Pluronic® samples. Although Pluronic® F127 is the one sample that remains the most
stable, its size is too large for possible, successful drug delivery and its PDI shows a wide
distribution in sizes of particles in the sample. Therefore, by this point, all three samples
have passed their threshold of stability.
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Changes in Z-average diameter size over 37
days in the three Pluronic® samples
3500
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Z-average size (nm)

2500
2000

PLURONIC F127 Z-average size
PLURONIC P85 Z-average size

1500

PLURONIC F68 Z-average size
1000
500
0
0

10

20
Number of Days

30

40

Figure 11. Changes in Z-average diameter size over 37 days in the three Pluronic®
samples

As can be seen from the data, Pluronic® P85 is not a good candidate for drug
delivery. Upon its first measurement, it is far too large to be a viable option for entering
the cell, and its large PDI value clearly shows that the particles within the samples are
many different sizes. Without a consistent size value throughout the sample, the
Pluronic® P85 redox-sensitive block copolymer micelle is not a reliable option for drug
delivery.
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The data for Pluronic® F68 and F127 show more promising results. Within the
time frame of a week, Pluronic® F68 is the best option for drug delivery, with the
smallest Z-average diameter size and lowest average PDI, demonstrating that the
nanoparticles are smaller and all within the same size range. However, after the threshold
of eight days, Pluronic® F127 is the most stable option. Its size varies the least over the
entire 37 days, although by the end, it is too large to be promising for drug delivery.
Although Pluronic® F68 and F127 show promising results for size and stability,
the consensus on the sizes limits of drug delivery system size is that drug delivery
systems must be smaller than or within the range of 200 nm for realistic drug delivery to
occur (Dreaden et al. 458). Therefore, the specific particles made in this experiment could
not be actual drug delivery systems. However, the promise of Pluronic® F68 and F127 in
polyQPA drug delivery systems is that further research can be done to decrease the size.
These two Pluronic® systems show excellent stability because they last in their general
size range for many days and even weeks, and they are not much too large to show
concerns for solvency and free dispersal. Therefore, if further research can be done to
decrease the actual structure size during nanoparticle synthesis, these two Pluronic®
systems show great promise for subsequent drug delivery.
Therefore, the best drug delivery option over the time period of a week or less is
Pluronic® 68, but if the sample must be stable for longer periods of time, Pluronic® F127
is the best option.
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Chemical reduction using sodium dithionite (Na2S2O4)
Pluronic® F68

Pluronic® P85

Pluronic® F127

Time 0

657.1 nm

1017 nm

624 nm

15 minutes

1149 nm

709.6 nm

687.9 nm

30 minutes

1313 nm

1209 nm

864.1 nm

50 minutes

1476 nm

730.1 nm

1245 nm

70 minutes

1512 nm

695.5 nm

1235 nm

90 minutes

1876 nm

853.7 nm

1143 nm

110 minutes

1794 nm

743.6 nm

979.8 nm

130 minutes

1723 nm

822 nm

1087 nm

Table 13. Change in Z-average size after addition of sodium dithionite over 130 minutes
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Change in Z-average size after addition of sodium
dithionite over 130 minutes
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Figure 12. Change in Z-average size after addition of sodium dithionite over 130 minutes
The data from the sodium dithionite experiment shows promising results for the
Pluronic® F68 and Pluronic® F127 particles, but show poor results for the Pluronic® P85
particles. The desired result for this experiment was for the particles to increase in size
from time zero to 130 minutes. An increase in size would mean that sodium dithionite
effectively reduced the polyQPA portion of the particles and thus carried out the
proposed mechanism from Figure 4. The resulting reduced particle would have a result as
shown in Figure 7. As a result, the individual units of the polyQPA-Pluronic® particles
dissociate from one another and an overall increase in size is the result, as shown in
Figure 7.
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For Pluronic® F68, the general trend is an increase in size until 110 minutes, after
which time the size begins to decrease slightly. The overall general increase however
does show that the polyQPA-Pluronic® F68 structure should be effective for future
incorporation and release of paclitaxel. For Pluronic® F127, the trend also was increase
but ended at 90 minutes, after which the size also decreased slightly. Nevertheless, these
results show promise as well for future incorporation and release of paclitaxel.
However, Pluronic® P85 showed very erratic results for changes in size over 130
minutes. Therefore, the polyQPA-Pluronic® P85 structure most likely does not support
the mechanism in Figure 4 and is not a good system for future incorporation and release
of paclitaxel. Another reason for the ineffectiveness of the polyQPA-Pluronic® P85
structure is that there was a mistake made in synthesis and the copolymeric nanoparticles
were not correctly made. This mistake would account for the problems in size and
stability and in sodium dithionite reduction.
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CONCLUSION
According to the results of the experiments, polyQPA-Pluronic® block
copolymeric nanoparticles are viable possibilities for future drug delivery. Both
polyQPA-Pluronic® F68 and F127 showed successful and promising results for size and
stability measurements as a well as sodium dithionite reduction. However, polyQPAPluronic® P85 showed erratic results for both experiments.
Conclusions can be drawn from the results of this experiment and thus can be
integrated into future research for redox-sensitive chemotherapy drug delivery systems.
First, Pluronic® was well incorporated with polyQPA. This conclusion can be drawn
because of the size difference between polyQPA-mPEG750 and polyQPA-Pluronic®. The
mean diameter of micelles of poly-mPEG750 in preliminary research was 27.50 nm
whereas the diameters of the various polyQPA-Pluronic® nanoparticles were at least 400
nm (Bae and Maurya et al. 5). Therefore, the Pluronic® changed the size of the particles,
and it also affected to the stability of the particles over time. Furthermore, it is known that
polyQPA can still perform its function of releasing QPA lactone is because the sodium
dithionite experiment was successful for polyQPA-Pluronic® F68 and F127.
The second conclusion that can be drawn from this experiment is that Pluronic®
with long PEO chains are more effective for stability like with Pluronic® F68 and F127.
This phenomenon is due to the fact that having more hydrophilic nature from PEO
prevents the hydrophobic portions of the molecules in polyQPA and hydrophobic PPO
portion of Pluronic® from self-aggregating and having low solvency. It keeps the size of
the particles smaller, and also allows them to remain stable and dispersed in solution with
time.
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The third conclusion that can be drawn from these results is that the simple
formulation method demonstrated by polyQPA-Pluronic® nanoparticles would be an
effective means to produce stable micelle drug delivery systems from hydrophobic
polymers (like polyQPA). Having a simple preparation process is valuable for time and
accuracy in the lab, and shows promising results for size, stability, and drug release
ability.
In summary, the results of this research show promise for the future of
chemotherapy and specifically paclitaxel drug delivery systems. Although the size of the
particles still remains too large for immediate drug delivery and all of these experiments
were performed in vitro away from the actual conditions present in an actual tumor cell,
the results of the research provide a promising start for future research.
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